Cuiping Pan

Cuiping Pan

Auto-generated profile, based on publicly available information

Cuiping Pan

Systems Hub, The Hong Kong University of Science and Technology (Guangzhou) Bioscience and Biomedical Engineering Thrust Guangzhou 511453

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2009 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
CPCuiping Pan
Cuiping Pan
CKChanchal Kumar
Chanchal Kumar
SBSebastian Bohl
Sebastian Bohl
UKUrsula Klingmueller
Ursula Klingmueller
MMMatthias Mann
Matthias Mann
Biological experiments are most often performed with immortalized cell lines because they are readily available and can be expanded without limitation. However, cell lines may differ from the in vivo situation in important aspects. Here we introduce a straightforward methodology to compare cell lines to their cognate primary cells and to derive a comparative functional phenotype. We used SILAC (stable isotope labeling by amino acids in cell culture) for quantitative, mass spectrometry-based comparison of the hepatoma cell line Hepa1–6 with primary hepatocytes. The resulting quantitative proteome of 4,063 proteins had an asymmetric distribution, with many proteins down-regulated in the cell line. Bioinformatic analysis of the quantitative proteomics phenotypes revealed that Hepa1–6 cells were deficient in mitochondria, reflecting re-arrangement of metabolic pathways, drastically up-regulate cell cycle-associated functions and largely shut down drug metabolizing enzymes characteristic for the liver. This quantitative knowledge of changes provides an important basis to adapt cell lines to more closely resemble physiological conditions.

12 March 2014 in JAMA
Verified
Journal Article
Open access
PDF file
FDFrederick E. Dewey
Frederick E. Dewey
MGMegan E. Grove
Megan E. Grove
CPCuiping Pan
Cuiping Pan
BGBenjamin A. Goldstein
Benjamin A. Goldstein
JBJonathan A. Bernstein
Jonathan A. Bernstein
TQThomas Quertermous
Thomas Quertermous
As technical barriers to human DNA sequencing decrease and the cost of whole-genome sequencing (WGS) approaches $1000, WGS and protein-coding genome sequencing (whole-exome sequencing [WES]) are increasingly used in clinical medicine. Both WGS/WES can successfully aid clinical diagnosis,1-3 reveal the genetic basis of rare familial diseases,4-6 and explicate novel disease biology.7,8 Regardless of context, even in apparently healthy individuals, WGS/WES are expected to uncover genetic findings of potential clinical importance.9-11 However, comprehensive clinical interpretation and reporting of clinically significant findings are seldom performed. As WGS/WES are applied more broadly, questions have been raised about the duty for discovery, interpretation, and reporting of clinical findings. Recently published recommendations define genetic variant types in a minimum list of inherited disease genes that are suggested to be subject to discovery, reporting, and clinical follow-up regardless of the primary indication for sequencing, patient preference, or patient age.12 Despite this, the technical sensitivity and reproducibility of clinical genetic findings using WGS and the clinical opportunities and costs associated with discovery and reporting of these and other clinical findings in WGS data remain undefined.

1 April 2020 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
HHHaley Hunter-Zinck
Haley Hunter-Zinck
YSYunling Shi
Yunling Shi
MLMan Li
Man Li
BGBryan R. Gorman
Bryan R. Gorman
SJSun-Gou Ji
Sun-Gou Ji
SPSaiju Pyarajan
Saiju Pyarajan

1 December 2009 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
CPCuiping Pan
Cuiping Pan
JOJesper V. Olsen
Jesper V. Olsen
HDHenrik Daub
Henrik Daub
MMMatthias Mann
Matthias Mann
Aberrant signaling causes many diseases, and manipulating signaling pathways with kinase inhibitors has emerged as a promising area of drug research. Most kinase inhibitors target the conserved ATP-binding pocket; therefore specificity is a major concern. Proteomics has previously been used to identify the direct targets of kinase inhibitors upon affinity purification from cellular extracts. Here we introduce a complementary approach to evaluate the effects of kinase inhibitors on the entire cell signaling network. We used triple labeling SILAC (stable isotope labeling by amino acids in cell culture) to compare cellular phosphorylation levels for control, epidermal growth factor stimulus, and growth factor combined with kinase inhibitors. Of thousands of phosphopeptides, less than 10% had a response pattern indicative of targets of U0126 and SB202190, two widely used MAPK inhibitors. Interestingly, 83% of the growth factor-induced phosphorylation events were affected by either or both inhibitors, showing quantitatively that early signaling processes are predominantly transmitted through the MAPK cascades. In contrast to MAPK inhibitors, dasatinib, a clinical drug directed against BCR-ABL, which is the cause of chronic myelogenous leukemia, affected nearly 1,000 phosphopeptides. In addition to the proximal effects on ABL and its immediate targets, dasatinib broadly affected the downstream MAPK pathways. Pathway mapping of regulated sites implicated a variety of cellular functions, such as chromosome remodeling, RNA splicing, and cytoskeletal organization, some of which have been described in the literature before. Our assay is streamlined and generic and could become a useful tool in kinase drug development.

28 August 2007 in Traffic
Verified
Journal Article
Open access
PDF file
BSBernd Schröder
Bernd Schröder
CWChristian Wrocklage
Christian Wrocklage
CPCuiping Pan
Cuiping Pan
RJRalf Jäger
Ralf Jäger
BKBernd Kösters
Bernd Kösters
AHAndrej Hasilik
Andrej Hasilik
We searched for novel proteins in lysosomal membranes, tentatively participating in molecular transport across the membrane and/or in interactions with other compartments. In membranes purified from placental lysosomes, we identified 58 proteins, known to reside at least partially in the lysosomal membrane. These included 17 polypeptides comprising or associated with the vacuolar adenosine triphosphatase. We report on additional 86 proteins that were significantly enriched in the lysosomal membrane fraction. Among these, 12 novel proteins of unknown functions were found. Three were orthologues of rat proteins that have been identified in tritosomes by Bagshaw RD et al. (A proteomic analysis of lysosomal integral membrane proteins reveals the diverse composition of the organelle. Mol Cell Proteomics 2005;4:133–143). Here, the proteins encoded by LOC201931 (FLJ38482) and LOC51622 (C7orf28A) were expressed with an appended fluorescent tag in HeLa cells and found to be present in lysosomal organelles. Among the lysosomally enriched proteins, also 16 enzymes and transporters were detected that had not been assigned to lysosomal membranes previously. Finally, our results identified a particular set of proteins with known functions in signaling and targeting to be at least partially associated with lysosomes.

7 March 2012 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
HLHugo Y K Lam
Hugo Y K Lam
CPCuiping Pan
Cuiping Pan
MCMichael J Clark
Michael J Clark
PLPhil Lacroute
Phil Lacroute
RCRui Chen
Rui Chen
MSMichael P Snyder
Michael P Snyder